Wow, this is huge, there is no current drug that does this, (I have highlighted)
"“At the heart of the problem in Parkinson’s lies the loss of dopamine producing neurons in the brain
due to toxicity caused by α-synuclein. There is now evidence that afamelanotide – by binding to
MC1R – could maintain stability and integrity of the affected neurons and slow down progression of
the disorder.
Ann: afamelanotide in fair-skinned Parkinsons patients, page-3
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.63 |
Change
0.120(0.89%) |
Mkt cap ! $682.3M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.77 | $13.43 | $581.2K | 42.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 248 | $13.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.64 | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |